LONDON, Ontario; BOSTON, Massachusetts – September 19, 2024 – TheNewswire – Sernova Corp. (TSX:SVA) (OTCQB:SEOVF) (FSE/XETRA:PSH), a clinical-stage biotechnology company focused on the development of regenerative medicine cell therapies for treatment of chronic diseases, announces today that David Paterson Ph.D. will join Sernova’s Board of Directors effective immediately.  

 

“I am pleased to have been able to attract David’s Paterson’s significant talent to Sernova’s Board of Directors,” said Jonathan Rigby, President and Chief Executive Officer of Sernova.  “Mr. Paterson brings more than 30 years of biotech experience with substantial contributions as both a senior executive, Board member and founder of numerous companies with a focus on corporate and business development, intellectual property generation and prosecution and alliance management.”

 

Mr. Paterson is currently employed at Colorado State University as Assistant Vice President for Research Translation and Commercialization where he manages strategic industry relationships.  In addition, he brings broad biopharma industry knowledge having worked for Impax Laboratories (IPXL: NASDAQ) in both Europe and North America where he provided leadership and Board support to the business development team for ten years until its acquisition by Amneal Pharmaceuticals (AMRX: NASDAQ).  Prior to Impax, Mr. Paterson held senior roles with Sepracor (Sunovion), GlaxoSmithKline and Skyepharma.  Mr. Paterson is also a co-founder of Neurogastrx, Inc helping to bring in early-stage capital.  Mr. Paterson has a Batchelor of Science from the University of Glasgow, a Ph.D. from the University of Illinois and was a Post-Doctoral Fellow in Molecular Genetics and Cellular Biology at the University of Chicago.

 

“I am very excited to be joining the Board of Sernova and offer up my scope of expertise to help the company grow and prosper within the type 1 diabetes space and to help open doors to new collaborations and further establish the Cell Pouch Transplantation System as a top tier technology within the Regenerative Medicine Cell Therapy sector,” said David Paterson.  

 

ABOUT SERNOVA AND ITS CELL POUCH SYSTEM PLATFORM FOR CELL THERAPY

 

Sernova Corp. is a clinical-stage biotechnology company that is developing therapeutic cell technologies for chronic diseases, including insulin-dependent diabetes, thyroid disease, and blood disorders that include hemophilia A. Sernova is currently focused on developing a ‘functional cure’ for insulin-dependent diabetes with its lead technology, the Cell Pouch System, a novel implantable and scalable medical device with immune protected therapeutic cells.

 

On implantation, The Cell Pouch forms a natural vascularized tissue environment in the body for long-term survival and function of therapeutic cells that release essential factors that are absent or deficient in the bodies of patients with certain chronic diseases. Sernova’s Cell Pouch System has demonstrated its potential to be a ‘functional cure’ for people with T1D in an ongoing Phase 1/2 clinical study at the University of Chicago.

 

Sernova partnered with Evotec to develop an implantable off-the-shelf iPSC (induced pluripotent stem cells) based islet replacement therapy. This partnership provides Sernova a potentially unlimited supply of insulin-producing cells to treat millions of patients with insulin-dependent diabetes (type 1 and type 2). Sernova’s development pipeline that uses its Cell Pouch System also includes: a cell therapy for hypothyroid disease resulting from thyroid gland removal and an ex vivo lentiviral Factor VIII gene therapy for hemophilia A.

 

FOR FURTHER INFORMATION, PLEASE CONTACT:

 

Christopher Barnes

VP, Investor Relations

Sernova Corp.

Tel: +1 519-902-7923

Email: christopher.barnes@sernova.com

Website: www.sernova.com

 

The TSX has not reviewed this news release and does not accept responsibility for the accuracy or adequacy of this news release.

FORWARD-LOOKING INFORMATION  

This release contains statements that, to the extent they are not recitations of historical facts, may constitute “forward-looking statements” that involve various risks, uncertainties, and assumptions, including, without limitation, statements regarding the prospects, plans, and objectives of the company. Wherever possible, but not always, words such as "expects", "plans", "anticipates", "believes", "intends", "estimates", "projects", "potential for" and similar expressions, or that events or conditions "will", "would", "may", "could" or "should" occur are used to identify forward-looking statements. These statements reflect management’s beliefs with respect to future events and are based on information currently available to management on the date such statements were made. Many factors could cause Sernova’s actual results, performances or achievements to not be as anticipated, estimated or intended or to differ materially from those expressed or implied by the forward-looking statements contained in this news release. Such factors could include, but are not limited to, the company’s ability to secure additional financing and licensing arrangements on reasonable terms, or at all; ability to conduct all required preclinical and clinical studies for the company’s Cell Pouch System and or related technologies, including the timing and results of those trials; ability to obtain all necessary regulatory approvals, or on a timely basis; ability to in-license additional complementary technologies; ability to execute its business strategy and successfully compete in the market; and the inherent risks associated with the development of biotechnology combination products generally. Many of the factors are beyond our control, including those caused by, related to, or impacted by the novel coronavirus pandemic. Investors should consult the company’s quarterly and annual filings available on www.sedarplus.ca for additional information on risks and uncertainties relating to the forward-looking statements. Sernova expressly disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.